[go: up one dir, main page]

TNSN97193A1 - Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents

Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.

Info

Publication number
TNSN97193A1
TNSN97193A1 TNTNSN97193A TNSN97193A TNSN97193A1 TN SN97193 A1 TNSN97193 A1 TN SN97193A1 TN TNSN97193 A TNTNSN97193 A TN TNSN97193A TN SN97193 A TNSN97193 A TN SN97193A TN SN97193 A1 TNSN97193 A1 TN SN97193A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
apo
amides
Prior art date
Application number
TNTNSN97193A
Other languages
English (en)
Inventor
Chang George
Joseph Quallich George
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97193A1 publication Critical patent/TNSN97193A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I..................DANS LAQUELLE G REPRESENTE DIVERS RADICAUX, ET LEURS STEREOISOMERES, SELS ET HYDRATES PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.APPLICATION : UTILISATION COMME INHIBITEURS DE ApoB/MTP DANS LE TRAITEMENT DE DIVERSES AFFECTIONS TELLES QUE L'ATHEROSCLEROSE, LA PANCREATITE, L'OBESITE, L'HYPERCHOLESTEROLEMIE, L'HYPERTRIGLYCERIDEMIE, L'HYPERLIPIDEMIE ET LE DIABETE.
TNTNSN97193A 1996-11-27 1997-11-26 Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. TNSN97193A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
TNSN97193A1 true TNSN97193A1 (fr) 2005-03-15

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97193A TNSN97193A1 (fr) 1996-11-27 1997-11-26 Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.

Country Status (34)

Country Link
US (1) US6121283A (fr)
EP (1) EP0944602A1 (fr)
JP (1) JP3270764B2 (fr)
KR (1) KR100334567B1 (fr)
CN (2) CN1238764A (fr)
AP (1) AP804A (fr)
AR (1) AR010309A1 (fr)
AU (1) AU716151B2 (fr)
BG (2) BG108830A (fr)
BR (1) BR9714364A (fr)
CA (1) CA2272719C (fr)
CZ (1) CZ292160B6 (fr)
DZ (1) DZ2358A1 (fr)
EA (1) EA001539B1 (fr)
GT (1) GT199700122A (fr)
HN (1) HN1997000144A (fr)
HR (1) HRP970642A2 (fr)
ID (1) ID18995A (fr)
IL (1) IL129744A0 (fr)
IS (1) IS5040A (fr)
MA (1) MA26451A1 (fr)
NO (1) NO312760B1 (fr)
NZ (1) NZ335162A (fr)
OA (1) OA11050A (fr)
PA (1) PA8441601A1 (fr)
PE (1) PE17199A1 (fr)
SK (1) SK65499A3 (fr)
TN (1) TNSN97193A1 (fr)
TR (1) TR199901180T2 (fr)
TW (1) TW502023B (fr)
UY (1) UY24789A1 (fr)
WO (1) WO1998023593A1 (fr)
YU (1) YU23499A (fr)
ZA (1) ZA9710641B (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DE69529849T2 (de) * 1995-06-07 2003-09-04 Pfizer Inc., New York Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
WO1999063929A2 (fr) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
JP2002527433A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンｄ３受容体のモジュレーター（抗精神病薬）として有用なテトラヒドロベンズアゼピン誘導体
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
IL143944A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
CN1342089A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆固醇酯转移蛋白抑制剂的组合
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
WO2001005767A1 (fr) * 1999-07-20 2001-01-25 Novartis Ag Composes organiques
CA2324801A1 (fr) * 1999-11-10 2001-05-10 Andrew Gordon Swick Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
CA2324800A1 (fr) * 1999-11-10 2001-05-10 Mary Anne Hickman Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp
IL139449A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
ATE295836T1 (de) * 2000-01-18 2005-06-15 Novartis Pharma Gmbh Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
AU2001260113B2 (en) * 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2001077077A1 (fr) * 2000-04-10 2001-10-18 Novartis Ag Derives d'(hetero)aryl-carboxamide en tant qu'inhibiteurs de la proteine microsomale de transfert des triglycerides (mtp) et de la secretion d'apolipoproteine b (apo b)
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
AU2001277728A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
CA2420951A1 (fr) * 2000-09-01 2003-02-28 Sankyo Company, Limited Compositions medicales
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
PL362546A1 (en) * 2000-10-05 2004-11-02 Fujisawa Pharmaceutical Co, Ltd. Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JP2004532856A (ja) * 2001-04-30 2004-10-28 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としてのビアリールカルボキサミド化合物
WO2003000235A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
DE60228447D1 (de) 2001-06-28 2008-10-02 Pfizer Prod Inc Triamidsubstituierte indole, benzofurane und benzothiophene als inhibitoren des mikrosomalen triglyceridtransferproteins (mtp) und/oder der sekretion von apolipoprotein b (apo b)
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US20030130343A1 (en) * 2001-08-10 2003-07-10 Adipogenix, Inc. Fat accumulation-modulating compounds
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
KR100717098B1 (ko) 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
NZ535366A (en) * 2002-03-13 2007-07-27 Univ Tennessee Res Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (fr) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
AU2003286347A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
EP1578725A1 (fr) * 2002-12-20 2005-09-28 Pfizer Products Inc. Inhibiteurs de proteine microsomale de transfert de triglyceride
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
EP1669345A4 (fr) * 2003-08-29 2008-02-20 Japan Tobacco Inc Derive d'ester et utilisation medicale de celui-ci
KR100848747B1 (ko) 2004-03-01 2008-07-25 액테리온 파마슈티칼 리미티드 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
WO2005087234A1 (fr) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania Traitement a faibles effets secondaires contre des affections liees a l'hyperlipidemie et l'hypercholesterolemie
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
EP1843819A2 (fr) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Procedes de reduction de la graisse corporelle
MX2007005137A (es) 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
ES2430319T3 (es) * 2005-04-19 2013-11-20 Surface Logix, Inc. Inhibidores de la secreción de la proteína microsomal de transferencia de triglicéridos y de la apo-B
WO2006129193A2 (fr) * 2005-05-27 2006-12-07 Pfizer Products Inc. Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
AU2007225273A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
EA201100812A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
JP5198430B2 (ja) 2006-04-03 2013-05-15 サンタリス ファーマ アー／エス ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
CA2654183A1 (fr) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions et procedes pour ameliorer l'hyperlipidemie
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
EP2076597A2 (fr) * 2006-10-09 2009-07-08 Santaris Pharma A/S Composés antagonistes de l'arn pour la modulation de pcsk9
WO2008045564A2 (fr) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
KR101387459B1 (ko) 2006-10-24 2014-05-14 얀센 파마슈티카 엔.브이. Ｍｔｐ를 저해하는 테트라하이드로-나프탈렌-1-카복실산 유도체
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008075949A1 (fr) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation de l'expression génique d'une protéine microsomale de transfert des triglycérides (mtp ou mttp) au moyen de microorganismes alimentaires ingérés/de qualité alimentaire
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
WO2008113830A1 (fr) * 2007-03-22 2008-09-25 Santaris Pharma A/S Composés arn antagonistes pour l'inhibition de l'expression de l'apo-b100
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
BRPI0813647A2 (pt) * 2007-06-25 2014-12-23 Neurogen Corp Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
DK2623599T3 (en) * 2007-10-04 2019-04-08 Roche Innovation Ct Copenhagen As Micromirers
DK2225261T3 (en) 2007-12-03 2016-06-06 Obe Therapy Biotechnology Borpeptidinhibitorer of enteropeptidase and their uses in the treatment of obesity, obesity and / or disorders associated with abnormal lipid metabolism
CA2708364A1 (fr) 2007-12-11 2009-06-18 Efrat Ben-Zeev Composes a base de carboxamide et leur utilisation en tant qu'agonistes du recepteur des chimiokines
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
WO2009109665A1 (fr) * 2008-03-07 2009-09-11 Santaris Pharma A/S Compositions pharmaceutiques pour le traitement de maladies associées aux microarn
WO2010012667A1 (fr) 2008-08-01 2010-02-04 Santaris Pharma A/S Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
EP2421970B1 (fr) * 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons
EP2456870A1 (fr) 2009-07-21 2012-05-30 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2014207232A1 (fr) 2013-06-27 2014-12-31 Santaris Pharma A/S Oligomères antisens et conjugués ciblant pcsk9
WO2015065595A1 (fr) 2013-10-30 2015-05-07 Trustees Of Dartmouth College Procédé d'inhibition sélective d'acat1 dans le traitement de l'obésité, du syndrome métabolique et de l'athérosclérose
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
JP2018502900A (ja) * 2014-10-22 2018-02-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN116322682A (zh) 2020-07-29 2023-06-23 艾米琳制药有限责任公司 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (fr) * 2023-04-13 2024-10-17 Acelot, Inc. Composés et méthodes de traitement de maladies à agrégation de protéines
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (fr) * 1995-06-07 2003-03-05 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)

Also Published As

Publication number Publication date
IL129744A0 (en) 2000-02-29
NO992525L (no) 1999-05-26
GT199700122A (es) 1999-05-19
US6121283A (en) 2000-09-19
TR199901180T2 (xx) 1999-08-23
PE17199A1 (es) 1999-02-19
CN1238764A (zh) 1999-12-15
SK65499A3 (en) 2001-05-10
CZ292160B6 (cs) 2003-08-13
IS5040A (is) 1999-04-30
DZ2358A1 (fr) 2002-12-28
CA2272719C (fr) 2002-10-01
EA001539B1 (ru) 2001-04-23
AR010309A1 (es) 2000-06-07
JP2000505810A (ja) 2000-05-16
KR20000057269A (ko) 2000-09-15
BG108830A (bg) 2005-10-31
NZ335162A (en) 2000-01-28
AP804A (en) 2000-01-28
BG103434A (en) 2000-07-31
NO312760B1 (no) 2002-07-01
CA2272719A1 (fr) 1998-06-04
MA26451A1 (fr) 2004-12-20
HRP970642A2 (en) 1998-10-31
NO992525D0 (no) 1999-05-26
JP3270764B2 (ja) 2002-04-02
ZA9710641B (en) 1999-05-26
KR100334567B1 (ko) 2002-05-03
AP9701145A0 (en) 1998-01-31
BR9714364A (pt) 2000-03-21
UY24789A1 (es) 2000-09-29
HN1997000144A (es) 1997-12-16
AU716151B2 (en) 2000-02-17
EA199900416A1 (ru) 1999-12-29
OA11050A (en) 2002-03-07
ID18995A (id) 1998-05-28
EP0944602A1 (fr) 1999-09-29
PA8441601A1 (es) 2000-05-24
CN1380289A (zh) 2002-11-20
AU4634797A (en) 1998-06-22
WO1998023593A1 (fr) 1998-06-04
TW502023B (en) 2002-09-11
YU23499A (sh) 2001-07-10

Similar Documents

Publication Publication Date Title
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN96085A1 (fr) Amides therapeutiques et compositions les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).